ArticleChinese medicine2025
Huanglian Jiedu Decoction improves the"central-peripheral"inflammatory microenvironment and enhances the cognitive function of APP/PS1 mice by inhibiting the activation of NLRP3 inflammasome mediated by gut microbiota.
Article in Chinese medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Therapeutic Potential of Jiedu Yizhi Formula for Alzheimer's Disease: A Randomized Controlled Trial.Chinese journal of integrative medicine · 2026Article
- The Associations Between Dietary Flavonoid Intake and Neurodegenerative Diseases Risk: A Cross-Sectional Study.Chemical biology & drug design · 2026Article
- Bridging Bench and Bytes: Syringic Acid and Nifuroxazide Reduce Stress-Induced Anxiety via NF-κB/NLRP3 Modulation and Docking Validation.Neurochemical research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundHuanglian Jiedu Decoction (HLJDD) is a representative formula for clearing heat and removing toxins, and some basic studies indicated that it can improve the learning cognitive ability of Alzheimer's disease (AD) mice, but the underlying molecular mechanism of its improvement in AD mice is still unclear, therefore, this paper delves into the mechanism of HLJDD to improve AD. PURPOSE: This study aims to investigate whether HLJDD can improve the "central-peripheral" inflammatory microenvironment in APP/PS1 mice, and to explore its relationship with gut microbiota and NLRP3 inflammatory vesicles activation. MATERIALS AND
methodsIn this paper, the fingerprint of HLJDD was established by high-performance liquid chromatography (HPLC) and the components of HLJDD were characterized by ultra-performance liquid chromatography-time-of-flight mass spectrometry (UPLC-O-TOF/MS). The potential signaling pathways of HLJDD against AD were preliminarily investigated through network pharmacology. Behavioral assessment, histopathological staining, immunofluorescence staining, immunohistochemical staining, and detection of central and peripheral inflammatory factors were used to explore the improvement of AD by HLJDD, in addition to which we examined the gut microbiota and expression of relevant inflammatory proteins.
resultsIn this study, 137 chemical constituents, including flavonoids, terpenoids, and alkaloids, were first identified in HLJDD by HPLC fingerprinting and UPLC-Q-TOF/MS. In addition, 49 components were found in the brain tissue of APP/PS1 mice and 48 components were found in the plasma of APP/PS1 mice. Network pharmacology concluded that the relevant pathways for HLJDD treatment of AD include inflammatory pathways. We found that HLJDD was effective in improving the learning memory ability of APP/PS1 mice by in vivo mouse behavioral performance. Histopathological results showed that HLJDD had the effect of reducing AD-like pathological damage, and also found that HLJDD could significantly reduce the proportion of M1 type microglia and A1 type astrocytes, and increase the proportion of M2 type microglia and A2 type astrocytes, and the treatment of HLJDD also suppressed the infiltration of CD4
conclusionTherefore, it is hypothesized that HLJDD improves the "central-peripheral" inflammatory microenvironment in APP/PS1 mice by inhibiting the activation of NLRP3 inflammatory vesicles mediated by gut microbiota.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.